Key facts
- Cardurion’s last known valuation is $760.0M.
- It has raised $621.8M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($260.0M) in Jul 2024.
- Notable investors include Fidelity Management & Research Company, GV, New Enterprise Associates, Blue Owl Capital, Bain Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Cardurion
Funding rounds
1 roundsAbout Cardurion
Developer of cardiovascular therapeutics intended to treat cardiovascular diseases. The company's therapeutics offer advanced novel mechanisms to develop new treatments for heart diseases, causing morbidity and mortality, enabling healthcare professionals to prevent arrhythmia disorders and heart failures.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2017
- Employees
- 50
- Website
- cardurion.com/
- Ownership
- Privately Held (backing)
Cardurion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cardurion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cardurion in its N-PORT filings yet. We sweep new filings monthly.